AVPR1A
ENSG00000166148
Target class
GPCR
Chromosome
12
Approved drugs
6
Clinical candidates (approved and in development)
13
- Approved drugs
- 6
- ClinGen gene-disease validity
- Disputed
- Clinical candidates (approved and in development)
- 13
- Chemical probe available
- Yes
- Target name
- AVPR1A
- Gene name
- Arginine vasopressin receptor 1A
- Gene symbol
- AVPR1A
- Previous gene symbols
- AVPR1
- Protein name
- Vasopressin V1a receptor (V1aR) (AVPR V1a) (Antidiuretic hormone receptor 1a) (Vascular/hepatic-type arginine vasopressin receptor)
- Gene biotype
- Protein coding
- Gene family
- Arginine vasopressin and oxytocin receptors
- Target class
- GPCR
- Target type
- Human gene
- Tissues expressed in
- 30
- Highest tissue expression
- 42.79
- Tissue specificity (Gini)
- 0.727
- Tissue specificity (tau)
- 0.9
- KEGG gene identifiers
- hsa:552
- Protein interaction confidence
- 0.876813
- Protein interaction partners
- 16
- R-HSA-388479
- R-HSA-416476
- R-HSA-5619099
- End position
- 63151201
- Start position
- 63142759
- Chromosome
- 12
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein.
- Tissue specificity (tau)
- 0.90021
- Expression inequality (Gini)
- 0.727495
Expression in transcripts per million
- Artery - Tibial
- 42.79
- Adrenal Gland
- 35.5
- Adipose - Visceral (Omentum)
- 23.24
- Adipose - Subcutaneous
- 22.94
- Cervix - Endocervix
- 17.65
Expression in transcripts per million
- Artery - Tibial42.79
- Adrenal Gland35.5
- Adipose - Visceral (Omentum)23.24
- Adipose - Subcutaneous22.94
- Cervix - Endocervix17.65
- Breast - Mammary Tissue13.66
- Thyroid13.55
- Cervix - Ectocervix13.13
- Uterus11.37
- Liver9.97
- Fallopian Tube9.02
- Vagina5.15
- Artery - Coronary4.88
- Bladder4.87
- Nerve - Tibial4.06
- Esophagus - Gastroesophageal Junction3.22
- Skin - Sun Exposed (Lower leg)2.96
- Prostate2.95
- Esophagus - Muscularis2.85
- Colon - Sigmoid2.66
- Kidney - Cortex2.34
- Skin - Not Sun Exposed (Suprapubic)1.93
- Minor Salivary Gland1.73
- Colon - Transverse1.58
- Artery - Aorta1.55
And 29 more, listed on the interactive page.
- GO:0006091
- GO:0007186
- GO:0007204
- GO:0008015
- GO:0005768
- GO:0005886
- GO:0030139
- GO:0005000
- GO:0005080
- GO:0005515
myocardial fibrosis
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: myocardial fibrosis
Biological samples
- cardiovascular system
Evidence sourceincreased urinary sodium excretion
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased urinary sodium excretion
- renal
- central nervous system
- cardiovascular
PubMed 28216264vasoconstriction
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: vasoconstriction
Biological samples
- cardiovascular system
Evidence sourcedecreased body temperature
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: decreased body temperature
- renal
- central nervous system
- cardiovascular
PubMed 28216264heart failure
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: heart failure
Biological samples
- cardiovascular system
Evidence sourcemyocardial hypertrophy
Effects
- Activation/Increase/Upregulation: chronic
Studies
- preclinical: myocardial hypertrophy
- renal
- central nervous system
- cardiovascular
PubMed 28216264increased blood pressure
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased blood pressure
- renal
- central nervous system
- cardiovascular
PubMed 28216264increased memory
Effects
- Activation/Increase/Upregulation: acute
Studies
- preclinical: increased memory
- renal
- central nervous system
- cardiovascular
PubMed 28216264decreased anxiety
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased anxiety
- renal
- central nervous system
- cardiovascular
PubMed 28216264hypertrophy
Effects
- Activation/Increase/Upregulation: general
Studies
- clinical: hypertrophy
Biological samples
- cardiovascular system
Evidence sourcedecreased urinary sodium excretion
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased urinary sodium excretion
- renal
- central nervous system
- cardiovascular
PubMed 28216264decreased aggression
Effects
- Inhibition/Decrease/Downregulation: acute
Studies
- preclinical: decreased aggression
- renal
- central nervous system
- cardiovascular
PubMed 28216264
increased blood pressure
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: increased blood pressure
- cardiovascular system
- renal
PubMed 23197038decreased heart rate
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: decreased heart rate
- cardiovascular system
- renal
PubMed 23197038hyponatraemia
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: hyponatraemia
- cardiovascular system
- renal
PubMed 23197038cardiac hypertrophy
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: cardiac hypertrophy
- cardiovascular system
- renal
PubMed 23197038myocardial fibrosis
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: myocardial fibrosis
- cardiovascular system
- renal
PubMed 23197038receptor binding
Studies
- biochemical: NVS_GPCR_hV1A, is one of one assay component(s) measured or calculated from the NVS_GPCR_hV1A assay. It is designed to make measurements of radioligand binding, a form of binding reporter, as detected with scintillation counting signals by Filter-based radiodetection technology.
Biological samples
- cell-free
Evidence sourcewater retention in body
Effects
- Activation/Increase/Upregulation: general
Studies
- preclinical: water retention in body
- cardiovascular system
- renal
PubMed 23197038
Related records
Trials (325)
- 1-deamino 8-d-arginine Vasopressin (DDAVP) in Percutaneous Ultrasound-guided Renal Biopsy
- 2- Day vs. 5- Day Terlipressin and Ceftriaxone in the Control Acute Gastroesophageal Variceal Hemorrhage
- A 6-week Open Label Cross-over Study With 2 Different Daily Doses of Minirin® Oral Lyophilisate in Children and Adolescents With Primary Nocturnal Enuresis (PNE)
- A New Check-list Method for Nocturnal Enuresis
- A Phase 1, Randomized, Double-blind, Placebo-controlled Crossover Study of RG7314 on the Potential Regulation of Higher Brain Functions in Healthy Male Participants: Proof of Mechanism
- A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
- A SAD/MAD Study of Safety, Tolerability and Pharmacologic Activity of BT200 in Normal Volunteers
- A Single-center Study to Investigate How Quickly and to What Extent a Radioactive Dose of RO5285119 is Absorbed, Metabolized and Eliminated From the Body of Healthy Male Volunteers
- A Study Investigating the Absolute Oral Bioavailability of Balovaptan After Single and Multiple Daily Oral Doses of Balovaptan in Healthy Volunteers
- A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
- A Study of Minirin Melt in Japanese Patients With Central Diabetes Insipidus (CDI).
- A Study of Multiple Dosing Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia
- A Study of RG7314 to Investigate Efficacy and Safety in Individuals With Autism Spectrum Disorders (ASD)
- A Study of RO5285119 in Healthy Volunteers
- A Study of Terlipressin in Patients With Hepatorenal Syndrome Type 1
- A Study of the Combination of Multiple Doses of RO5285119 With a Single Dose of Risperidone in Healthy Volunteers
- A Study of the Effect of Multiple Doses of Itraconazole and Fluoxetine on the Pharmacokinetics of a Single Dose of RO5285119 in Healthy Subjects
- A Study to Assess the Effect of Severe Hepatic Impairment on the Pharmacokinetics of Intravenous Conivaptan
- A Study to Assess the Efficacy, Safety and Pharmacokinetics of Intravenous Conivaptan (Vaprisol®) in Pediatric Subjects With Euvolemic or Hypervolemic Hyponatremia
- A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients
Drugs (15)
- Argipressin tannate Vasopressin receptor agonist
- Balovaptan Vasopressin V1a receptor antagonist
- Conivaptan Vasopressin V1a receptor antagonist
- Conivaptan hydrochloride Vasopressin V1a receptor antagonist
- Desmopressin Vasopressin receptor agonist
- Desmopressin acetate Vasopressin receptor agonist
- Lypressin Vasopressin receptor agonist
- Pecavaptan Vasopressin V1a receptor antagonist
- Relcovaptan Vasopressin V1a receptor antagonist
- Selepressin Vasopressin V1a receptor agonist
- SRX246 Vasopressin V1a receptor antagonist
- SRX251 Vasopressin V1a receptor antagonist
- Terlipressin Vasopressin V1 receptor binding agent
- Vasopressin Vasopressin receptor agonist
- Vasopressin tannate Vasopressin V1a receptor agonist